A Call For Action: Pharma Strategies For Development Of Payor Evidence Programs
The biopharma industry invests substantially in post-approval studies to convey information about the value of its products to constituents, but the majority of these efforts do not address core, real-world questions raised by payors. A new business model recognizing the strategic value of medical affairs to market access is needed to stem the tide of disappointing reimbursement decisions.
You may also be interested in...
Manufacturers, payers and providers will need to learn how to trust each other’s data sources if the benefits of the big datasets of real-world evidence are to be realized, pharmaceutical execs say.
Pharmaceutical companies are beginning to leverage big data to become more integrated into health care delivery, looking to care coordination and other “services adjacent to medicines,” IBM’s John Piccone reports.
All too often, pharmaceutical companies and investors put up hurdles, but they can and must identify indications and assets with high future market access potential in early stages by adjusting the early screening and evaluation process.